Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Temanogrel
APD791 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| APD791 | DRUG | APD791 or matching placebo in escalating doses |
APD791 is an investigational small molecule therapeutic developed by Pfizer, Inc. It has been studied in Phase 1 clinical trials involving healthy volunteers. The specific disease indications for APD791 have not been publicly disclosed, and the program is categorized under a therapeutic area outside the main oncology, immunology, or neurology categories.
APD791 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer sponsored the Phase 1 clinical trials of APD791 that have been conducted to date.
APD791 is in Phase 1 clinical development. It has completed two Phase 1 trials with a combined total enrollment of 140 healthy volunteers. No active trials are currently listed for APD791, and the drug has not been approved by the FDA for any indication.
APD791 has been evaluated in two completed Phase 1 trials. NCT00619931 was a multiple-dose study assessing safety, tolerability, and steady-state pharmacokinetics of APD791 in 50 healthy volunteers. NCT00529646 was a single-dose safety study of APD791 in 90 healthy volunteers. Both trials are listed as completed.
No, APD791 is not FDA approved. It remains an investigational drug that has completed Phase 1 clinical testing. Both of its Phase 1 trials, NCT00619931 and NCT00529646, were conducted in healthy volunteers and are now completed, with no active trials currently listed.